Mesna Cell (Mesna)

Mesna contains free sulfhydryl groups that rapidly react with acrolein, the harmful by‑product formed when cyclophosphamide or ifosfamide is metabolized. The resulting conjugate is non‑toxic and is eliminated in the urine, thereby shielding the bladder epithelium from chemical injury. This chemical neutralisation is the primary mechanism by which Mesna provides uroprotection.

The dose of Mesna is individualized by the prescribing oncologist or pharmacist based on the specific chemotherapy regimen, patient weight, renal function, and timing of cyclophosphamide or ifosfamide administration. Standard practice involves dosing before, during, and after the alkylating agent, but exact amounts and intervals must be determined by the treating clinician.

Safety data for Mesna during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Breastfeeding mothers should discuss potential exposure with their healthcare provider, as the drug may be excreted in milk.

To order Mesna Cell, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details—including cold‑chain handling if needed—and assists with any required import documentation.

The primary alternative to Mesna for protecting the bladder from cyclophosphamide‑derived acrolein is no prophylaxis, as few agents offer comparable chemical inactivation. Sodium thiosulfate is used for cisplatin‑induced ototoxicity, not for acrolein. Consequently, Mesna remains the standard of care for hemorrhagic cystitis prevention, offering a well‑characterised safety profile and direct neutralisation of the offending metabolite.

Mesna Cell should be stored at 2 °C to 8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Before use, inspect for particulate matter or discoloration, and follow aseptic techniques when diluting for intravenous administration.

Mesna Cell is supplied as a sterile solution for injection and is administered intravenously. It is typically diluted in compatible IV fluid and infused over a short period before, during, and after the cyclophosphamide or ifosfamide infusion, according to the schedule prescribed by the oncologist. Administration must be performed by trained medical personnel in a clinical setting.

The most serious adverse reactions associated with Mesna include anaphylaxis, severe hypotension, pulmonary edema, hemolysis, and rare severe skin disorders such as Stevens‑Johnson syndrome. Patients should be monitored closely for signs of allergic reaction, sudden blood pressure drops, respiratory difficulty, or unexplained bruising, and any such events require immediate medical intervention.

Mesna Cell is contraindicated in individuals with a known hypersensitivity to mesna or any of its excipients. Caution is also advised for patients with severe renal impairment, as reduced clearance may increase exposure. Pregnant or breastfeeding women should only use the product when the expected benefit justifies potential risks, and it should be avoided in patients for whom alternative uroprotective strategies are more appropriate.